WORK Medical raises $2.1M in private placement

WORK Medical Technology Group LTD (WOK) reports closing a private placement of new equity.

Rhea-AI Filing Summary

WORK Medical Technology Group LTD (WOK) reports closing a private placement of new equity. The company issued 2,000,000 Class A ordinary shares at $1.00 per share and 50,000 Class B ordinary shares at $2.50 per share under securities purchase agreements with certain investors. The transaction closed on August 18, 2026 and generated aggregate gross proceeds of approximately $2,125,000, which the company intends to use for business expansion, working capital and general corporate purposes.

The shares were sold in an offshore private placement relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration, with investors representing they are not U.S. persons and no general solicitation used. After the closing, 4,416,569 Class A and 51,009 Class B ordinary shares were issued and outstanding.

Filing Explained

The filing adds that the completed private placement report is incorporated by reference into the company’s Form F-3 registration statement; the disclosure still describes the shares as issued under registration exemptions, not as registered or publicly offered shares.

Key Figures

Class A shares issued: 2,000,000 shares Class B shares issued: 50,000 shares Subscription price Class A: $1.00 per share +4 more

7 metrics

Class A shares issued 2,000,000 shares Class A ordinary shares sold in the private placement at $1.00 per share

Class B shares issued 50,000 shares Class B ordinary shares sold in the private placement at $2.50 per share

Subscription price Class A $1.00 per share Price for Class A ordinary shares in the private placement

Subscription price Class B $2.50 per share Price for Class B ordinary shares in the private placement

Gross proceeds $2,125,000 Aggregate gross proceeds from the private placement

Class A shares outstanding post-transaction 4,416,569 shares Class A ordinary shares issued and outstanding immediately after closing

Class B shares outstanding post-transaction 51,009 shares Class B ordinary shares issued and outstanding immediately after closing

Key Terms

Private Placement, Regulation S, Section 4(a)(2), U.S. person, +1 more

5 terms

Private Placement financial

"the Company agreed to issue and sell, in a private placement (the “Private Placement”)"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Regulation S regulatory

"in reliance upon the exemptions ... pursuant to Section 4(a)(2) thereof, and Regulation S promulgated"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

Section 4(a)(2) regulatory

"in reliance upon the exemptions from the registration requirements ... pursuant to Section 4(a)(2)"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

U.S. person regulatory

"Each Investor represented that it is not a “U.S. person” in accordance with Regulation S"

A U.S. person is anyone or any entity treated as subject to U.S. rules for taxes, securities and other regulations — typically U.S. citizens, lawful permanent residents, people who live in the U.S. long-term, and companies, trusts or estates organized under U.S. law. It matters to investors because being classified as a U.S. person can determine what investments you may buy, what disclosures or reports are required, and which tax and compliance obligations apply, like a membership badge that decides which rulebook governs you.

incorporated by reference regulatory

"This report shall be deemed to be incorporated by reference into the registration statement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What capital did WORK Medical Technology Group LTD (WOK) raise in the August 2026 private placement?

WORK Medical Technology Group LTD raised approximately $2,125,000 in gross proceeds by issuing 2,000,000 Class A shares at $1.00 and 50,000 Class B shares at $2.50 in a private placement that closed on August 18, 2026.

How will WOK use the proceeds from the August 2026 private placement?

The company plans to use the approximately $2,125,000 in gross proceeds for business expansion, working capital and general corporate purposes, according to its disclosure.

How many WORK Medical Technology Group LTD (WOK) shares are outstanding after the private placement?

Immediately after the private placement, WORK Medical Technology Group LTD had 4,416,569 Class A ordinary shares and 51,009 Class B ordinary shares issued and outstanding.

What types of shares did WOK issue in the August 2026 private placement and at what prices?

WORK Medical Technology Group LTD issued 2,000,000 Class A ordinary shares at a subscription price of $1.00 per share and 50,000 Class B ordinary shares at a subscription price of $2.50 per share.

Under which exemptions did WOK conduct the August 2026 private placement?

The offering relied on exemptions from Securities Act registration under Section 4(a)(2) and Regulation S. Investors represented they are not U.S. persons, and the company stated it did not use general solicitation or public offering methods.

Is the August 2026 private placement information incorporated into WOK’s Form F-3 shelf registration?

Yes. The report states it is deemed incorporated by reference into WORK Medical Technology Group LTD’s Form F-3 registration statement (File No. 333-289943) and is part of that registration from the filing date, unless later superseded.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:30 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:30 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-42256

WORK Medical Technology Group LTD

1/88 Cook St, Auckland City, 1001, New Zealand

+1 949-818-3667
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

As previously disclosed, on August 4, 2026, WORK Medical Technology Group LTD, a Cayman Islands exempted company with limited liability (the “Company”) entered into certain securities purchase agreements (the “Securities Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”) ordinary shares, including 2,000,000 Class A ordinary shares, par value US$0.001 per share (the “Class A Ordinary Shares”) at the subscription price of $1.00 per share, and 50,000 Class B ordinary shares, par value US$0.001 per share (the “Class B Ordinary Shares”) at the subscription price of $2.50 per share.

The Private Placement closed on August 18, 2026. The Company received aggregate gross proceeds of approximately $2,125,000 from the Private Placement and intends to use the proceeds for business expansion, working capital and general corporate purposes. The Class A Ordinary Shares and the Class B Ordinary Shares were issued and sold by the Company to the Investors in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof, and Regulation S promulgated thereunder. Each Investor represented that it is not a “U.S. person” in accordance with Regulation S under the Securities Act. The Company did not engage in general solicitation or advertising and did not offer securities to the public in connection with the issuance and sale of the Class A Ordinary Shares or the Class B Ordinary Shares described in this report.

Immediately following the closing of the Private Placement, the Company had 4,416,569 Class A Ordinary Shares and 51,009 Class B Ordinary Shares issued and outstanding.

This report shall be deemed to be incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-289943) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	WORK Medical Technology Group LTD
Date: August 24, 2026	By:	/s/ Shuang Wu
	Name:	Shuang Wu
	Title:	Chief Executive Director

2